Cardiovascular (cMRI) identified that left bundle branch block (LBBB) does not significantly alter left atrial (LA) strain parameters in patients with ischemic or nonischemic dilated cardiomyopathy ...

A nationwide Optum claims cohort (413,450 PMOS; 2,067,250 controls) showed composite ASCVD incidence 4.52 vs 0.78 per 1000 person-years and an adjusted HR of 4.40. Coronary artery disease, ...

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next. The biggest obstacle to translating retina’s technology ...

Modeling of 82 brand drugs with ≥$100 million Medicaid spend found net prices exceeded at least one international reference price for more than 90% of products. State-level gains were heterogeneous, ...

Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...

A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab. As presented at EHA 2026, AGAVE-201 showed no significant ...

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...

Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key ...

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer ...

Linvoseltamab-gcpt is now a preferred treatment for multiple myeloma after 4 prior therapies, joining other bispecific antibodies in the NCCN guidelines. The FDA granted accelerated approval to ...